Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis

Journal of Neuroimmunology

Volumn 215, Issue 1-2, 2009, Pages 108-116

  Petersen, Thor ^a   Møller Larsen, Anné ^b   Thiel, Steffen ^b   Brudek, Tomasz ^b   Hansen, Troels Krarup ^c   Christensen, Tove ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Research Laboratory D   (Denmark)

Author keywords

Complement activation; Cytokines; HERV H; HERV W; Interferon beta; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; CYTOKINE; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MANNAN BINDING LECTIN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADULT; ANTIGEN ANTIBODY REACTION; ARTICLE; CLINICAL ARTICLE; COMPLEMENT LECTIN PATHWAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; ENDOGENOUS RETROVIRUS; FEMALE; HUMAN; INNATE IMMUNITY; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RETROVIRUS; TH1 CELL; TH2 CELL; UPREGULATION; VIRUS IMMUNITY;

ADULT; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; CYTOKINES; ENDOGENOUS RETROVIRUSES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, INNATE; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 70349813785     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.08.015     Document Type: Article

References (59)

1. Antony J.M., Van Marle G., Opii W., Butterfield D.A., Mallet F., Yong V.W., Wallace J.L., Deacon R.M., Warren K., and Power C. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat. Neurosci. 7 (2004) 1088-1095
2. Bangham C. HTLV-1 infections. J. Clin. Pathol. 53 (2000) 581-586
3. Barnett M.H., and Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55 (2004) 458-468
4. Baron S., Tyring S.K., Fleischmann Jr. W.R., Coppenhaver D.H., Niesel D.W., Klimpel G.R., Stanton G.J., and Hughes T.K. The interferons. Mechanisms of action and clinical applications. JAMA 266 (1991) 1375-1383
5. Berger T., and Reindl M. Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J. Neurol. Sci. 259 (2007) 21-26
6. Blond J.L., Beseme F., Duret L., Bouton O., Bedin F., Perron H., Mandrand B., and Mallet F. Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family. J. Virol. 73 (1999) 1175-1185
7. Burbelo P.D., Meoli E., Leahy H.P., Graham J., Yao K., Oh U., Janik J.E., Mahieux R., Kashanchi F., Iadarola M.J., and Jacobson S. Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 5 (2008) 96
8. Carrieri P.B., Ladogana P., Di Spigna G., de Leva M.F., Petracca M., Montella S., Buonavolontà L., Florio C., and Postiglione L. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders. Immunopharmacol. Immunotoxicol. 30 (2008) 1-9
9. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev. Med. Virol. 15 (2005) 179-211
10. Christensen T. Retroviruses in autoimmunity. In: Pandalai S.G. (Ed). Recent Research Developments in Immunology vol. 7 (2006), Research Signpost, Kerala 25-43
11. Christensen T., Møller-Larsen A., and Haahr S. A retroviral implication in multiple sclerosis?. Trends Microbiol. 2 (1994) 332-336
12. Christensen T., Dissing Sørensen P., Hansen H.J., and Møller-Larsen A. Antibodies against a human endogenous retrovirus and the preponderance of env splice variants in multiple sclerosis patients. Mult. Scler. 9 (2003) 6-15
13. Christensen T., Petersen T., Thiel S., Brudek T., Ellermann-Eriksen E., and Møller-Larsen A. Gene-environment interactions in multiple sclerosis: innate and adaptive immune responses to human endogenous retrovirus and herpes virus antigens and the lectin complement activation pathway. J. Neuroimmunol. 183 (2007) 175-188
14. Christiansen O.B., Kilpatrick D.C., Souter V., Varming K., Thiel S., and Jensenius J.C. Mannose-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scand. J. Immunol. 49 (1999) 193-196
15. Comabella M., Río J., Espejo C., Ruiz de Villa M., Al-Zayat H., Nos C., Deisenhammer F., Baranzini S.E., Nonell L., López C., Julià E., Oksenberg J.R., and Montalban X. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 130 (2009) 145-150
16. Dahl M.R., Thiel S., Matsushita M., Fujita T., Willis A.C., Christensen T., Vorup-Jensen T., and Jensenius J.C. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 15 (2001) 127-135
17. de Parseval N., Lazar V., Casella J.F., Benit L., and Heidmann T. Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins. J. Virol. 77 (2003) 10414-10422
18. Fernald G.H., Knott S., Pachner A., Caillier S.J., Narayan K., Oksenberg J.R., Mousavi P., and Baranzini S.E. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J. Immunol. 178 (2007) 5076-5085
19. Filippi M., and Rocca M.A. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J. Neurol. 252 S5 (2005) 16-24
20. Francis G., Weber F., and Rieckmann P. Effect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1b. Neurology 55 (2000) 322-323
21. Funding M., Hansen T.K., Gjedsted J., and Ehlers N. Simultaneous quantification of 17 immune mediators in aqueous humour from patients with corneal rejection. Acta Ophthalmol. Scand. 84 (2006) 759-765
22. Hafler D. Multiple sclerosis. J. Clin. Invest. 113 (2004) 788-794
23. Graber J.J., Ford D., Zhan M., Francis G., Panitch H., and Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J. Neuroimmunol. 185 (2007) 168-174
24. Hogancamp W.E., Rodriguez M., and Weinshenker B.G. The epidemiology of multiple sclerosis. Mayo Clin. Proc. 72 (1997) 871-878
25. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120 (1997) 865-916
26. Holmskov U., Thiel S., and Jensenius J.C. Collectins and ficolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol. 21 (2003) 547-578
27. Jacobs L., and Johnson K.P. A brief history of the use of interferons as treatment of multiple sclerosis. Arch. Neurol. 51 (1994) 1245-1252
28. Koch-Henriksen N., Sørensen P.S., Christensen T., Frederiksen J., Ravnborg M., Jensen K., Heltberg A., Kristensen O., Stenager E., Petersen T., Hansen T., and Danish Multiple Sclerosis Group. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66 (2006) 1056-1060
29. Kornek B., and Lassmann H. Neuropathology of multiple sclerosis - new concepts. Brain Res. Bull. 6 (2003) 321-326
30. Kozovska M.E., Hong J., Zang Y.C., Li S., Rivera V.M., Killian J.M., and Zhang J.Z. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 53 (1999) 1692-1697
31. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
32. Lassmann H., Bruck W., and Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7 (2001) 115-121
33. Lindeskog M., Mager D.L., and Blomberg J. Isolation of a human endogenous retroviral HERV-H element with an open env reading frame. Virology 258 (1999) 441-450
34. Mameli G., Serra C., Astone V., Castellazzi M., Poddighe L., Fainardi E., Neri W., Granieri E., and Dolei A. Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy. J. Neurovirol. 14 (2008) 73-77
35. Moller-Kristensen M., Jensenius J.C., Jensen L., Thielens N., Rossi V., Arlaud G., and Thiel S. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J. Immunol. Methods 282 (2003) 159-167
36. Moller-Kristensen M., Thiel S., and Jensenius J.C. MBL polymorphisms and infectious diseases. In: Vasta G.R., and Ahmed H. (Eds). Animal Lectins, a Functional View (2007), CRC Press, Boca Raton, FL Chapter 22
37. Nicoletti F., Di Marco R., Patti F., Zaccone P., L'Episcopo M.R., Reggio E., Xiang M., Nicoletti A., and Reggio A. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha. Cytokine 12 (2000) 682-687
38. Oh U., Yamano Y., Mora C.A., Ohayon J., Bagnato F., Buttman J., Dambrosia J., Leist T., McFarland H.F., and Jacobson S. Interferon-β1a therapy for HTLV-I-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) reduces HTLV-I-specific CD8+ T cells: analysis of HAM/TSP biomarkers. Ann. Neurol. 57 (2005) 526-534
39. Poser C.M., Paty D.W., Scheinberg L.C., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., and Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
40. Power C. Retroviral diseases of the nervous system: pathogenic host response or viral gene-mediated neurovirulence?. Trends Neurosci. 24 (2001) 162-169
41. Rep M.H., Hintzen R.Q., Polman C.H., and van Lier R.A. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67 (1996) 111-118
42. Rudick R.A., Ransohoff R.M., Peppler R., Vanderbrug Medendorg S., Lehmann P., and Alan J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 40 (1996) 618-627
43. Salama H.H., Kolar O.J., Zang Y.C., and Zhang J. Effects of combination therapy of IFNbeta-1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Mult. Scler. 9 (2003) 28-31
44. Sellner J., Greeve I., Findling O., Kamm C.P., Minten C., Engelhardt B., Grandgirard D., Leib S.L., and Mattle H.P. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis. Neurochem. Int. 53 (2008) 17-21
45. Sorensen P.S., Ross C., Clemmesen K.M., Bendtzen K., Frederiksen J.L., Jensen K., Kristensen O., Petersen T., Rasmussen S., Ravnborg M., Stenager E., Koch-Henriksen N., and Danish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362 (2003) 1184-1191
46. Steinman L. Nuanced roles of cytokines in three major human brain disorders. Clin. Invest. 118 (2008) 3557-3563
47. Stengaard-Pedersen K., Thiel S., Gadjeva M., Moller-Kristensen M., Sorensen R., Jensen L.T., Sjoholm A.G., Fugger L., and Jensenius J.C. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N. Engl. J. Med. 349 (2003) 554-614
48. Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol. Immunol. 44 (2007) 3875-3888
49. Thiel S., Vorup-Jensen T., Stover C.M., Schwaeble W., Laursen S.B., Poulsen K., Willis A.C., Eggleton P., Hansen S., Holmskov U., Reid K.B., and Jensenius J.C. A second serine protease associated with mannan-binding lectin that activates complement. Nature 386 (1997) 506-510
50. Thiel S., Holmvad S.H., Dahl M., and Jensenius J.C. An assay for mannan-binding lectin (MBL) associated serine protease 3, MASP-3. Mol. Immunol. 43 (2006) 122-191
51. Thiel S., Steffensen R., Christensen I.J., Ip W.K., Lau Y.L., Reason I.J., Eiberg H., Gadjeva M., Ruseva M., and Jensenius J.C. Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun. 8 (2007) 154-163
52. Ulvestad E., Aarseth J.H., Vedeler C., Nyland H., and Myhr K.M. The effects of interferon-alpha2a on concentrations of immunoglobulins, complement and lymphocytes in patients with multiple sclerosis. Scand. J. Immunol. 59 (2004) 103-108
53. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity 25 (2006) 343-348
54. Wandinger K.P., Sturzebecher C.S., Bielekova B., Detore G., Rosenwald A., Staudt L.M., McFarland H.F., and Martin R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 50 (2001) 349-357
55. Weinshenker B.G., Bass B., Rice G.P., Noseworthy J., Carriere W., Baskerville J., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 112 (1989) 133-146
56. Weinstock-Guttman B., Ramanathan M., and Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin. Biol. Ther. 8 (2008) 1435-1447
57. Wiesemann E., Deb M., Hemmer B., Radeke H.H., and Windhagen A. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin. Immunol. 128 (2008) 306-313
58. Xu V., Kulkovsky J., Acheampong E., Nunnari G., Sullivan J., and Pomerantz R.J. HIV-1-mediated apoptosis of neuronal cells: proximal molecular mechanisms of HIV-1-induced encephalopathy. Proc. Natl. Acad. Sci. USA 101 (2004) 7070-7075
59. Ytting H., Christensen I.J., Thiel S., Jensenius J.C., Svendsen M.N., Nielsen L., Lottenburger T., and Nielsen H.J. Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand. J. Immunol. 66 (2007) 458-464